Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive tumor affecting the synovium.1 It is non-malignant and predominantly non–life-threatening but can have a significant impact on patients’ quality of life.1,2
5 and 45
Per Million
Patient-Years
Patient-Years
Incidence of TGCT diffuse-type (D-TGCT) and nodular-type (N-TGCT),
respectively3
35–50
Years
Typical age at diagnosis of TGCT1
PVNS/GCTTS
TGCT has previously been referred to as pigmented villonodular
synovitis (PVNS) or giant cell tumor of tendon sheath (GCTTS)1
The symptoms of TGCT are generally nonspecific.4 Commonly reported symptoms include:
Pain1,4 
Swelling1,4 
Limited Rangeof Motion1,4
Stiffness1,4 TGCT tumor subtypes
TGCT comprises two clinically distinct subgroups, diffuse-type (D-TGCT) and nodular-type* (N-TGCT).1
TGCT can involve any joint. However, most N-TGCT affect the hand and wrist followed by knee, while most D-TGCT arise from the knee followed by the ankle and hip. Tumors may also be intra- or extra-articular.1,2
CLICK THE D-TGCT BOX TO FIND OUT MORE
- Most common subtype – accounts for ≈90% of cases5
- Impacts smaller joints, like fingers or wrists6
- Tumors are typically a single, well-defined mass6
- Often does not cause pain or joint dysfunction6
- Less common – accounts for ≈10% of cases5
- Impacts larger joints, like the knee, hips or ankles1,6
- Tumors are more aggressive and destructive; they can extend beyond the joint and damage surrounding bone6
Click here to explore the